Investigation of leptomeningeal disease in high grade glioma and characterization of molecular alterations
Madison Shoaf, Michael Glantz, Kyle Tuohy, Frances Chow, Joanne Xiu, Sonikpreet Aulakh, David Ashley, Eric Lipp, Giselle López, Ashley
Sumrall, Phillip Walker, David Spetzler, Theodore Nicolaides, Manmeet Ahluwalia, Katherine Peters
Leptomeningeal disease (LMD) is a challenging complication of high grade glioma (HGG) and questions remain regarding risk factors, molecular associations, and optimal treatment. Here we report updated results on a larger cohort from our previously reported multicenter study (Shoaf et al. 2022, NeuroOncology [Abstract]).
Patients with molecularly-profiled HGG (Caris Life Sciences; Phoenix, AZ) with LMD at 3 institutions were included. Medical records were reviewed for clinicopathologic characteristics and outcome, and Next Generation Sequencing was performed.